Search

The article reports that legislation permitting the U.S. government to negotiate Medicare drug prices has been weakened after pushback from the pharmaceutical industry. Topics include government's costs for filling prescriptions in federal programs; and medications by means of the National Institutes of Health (NIH) to fund biomedical research.

The article focuses on the implications of high-cost generic drugs on patients and policymakers in the U.S. Topics discussed include the need for the Food and Drug Administration (FDA) to create a way to promote competition and allow private market to function effectively, standard processing of generic drug approval, link of generic drug shortage with increase in price, and importance of implementing regulation to reduce price of older generic drugs.